Following positive Phase II data earlier in 2020, Acceleron Pharma’s experimental pulmonary arterial hypertension (PAH) treatment sotatercept won Breakthrough Therapy designation from the U.S. Food and Drug Administration.
If you are not happy with the results below please do another search
50 search results for:
AstraZeneca made an announcement describing the company’s internal and partnering efforts to battle COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, including an internal project on antibodies.
As the COVID-10 pandemic progresses, researchers are attacking the virus from every angle, and also learning more and more about how and why the virus affects who it does.
Eli Lilly and Sanofi, two of the largest manufacturers of insulin products, are responding to those in need of such life-saving drugs during the COVID-19 pandemic with programs that will provide continued access to insulin medication.
Following a setback with the company’s experimental major depressive disorder medicine in December, SAGE Therapeutics will initiate a corporate restructuring that includes halving the drug manufacturer’s employee headcount in order to focus resources on the development of the product pipeline.
U.S. officials warned Americans to expect alarming numbers of coronavirus deaths this week, even as an influential university model scaled back the projected U.S. pandemic death toll by 26 percent to 60,000.
Waltham, Massachusetts-based Arrakis Therapeutics inked a strategic collaboration and license deal with Roche focused on discovering RNA-targeted small molecule (rSM) drugs against a range of targets across all of the Swiss pharma giant’s research and development areas.
London, UK-based Wellcome Trust, a research-charity, is working to raise $8 billion to battle COVID-19. The initiative is called the COVID-Zero, and the goal is to raise the funds by the end of April.
A new report from the U.S. Centers for Disease Control and Prevention (CDC) confirms that in the majority of juveniles infected with COVID-19, the symptoms are less severe than in adult patients.
Only a week after ARCH Venture Partners and Flagship Pioneering raised huge venture capital funds aimed at life sciences, Deerfield Management announced the closing of the Deerfield Healthcare Innovations Fund II with $840 million.